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Novelty and Impact 
 
Directly measured circulating vitamin B12 was positively associated with overall lung cancer 
risk in 5,183 case-control pairs from 20 prospective cohorts. These findings were confirmed 
using a Mendelian randomization approach based on genetic data from 29,266 lung cancer 
cases and 56,450 controls. Our findings support the hypothesis that high circulating vitamin 







Vitamin B supplementation can have side effects for human health, including cancer 
risk. We aimed to elucidate the role of vitamin B12 in lung cancer aetiology via direct 
measurements of pre-diagnostic circulating vitamin B12 concentrations in a nested case-
control study, complemented with a Mendelian randomization (MR) approach in an 
independent case-control sample. We used pre-diagnostic biomarker data from 5,183 case-
control pairs nested within 20 prospective cohorts, and genetic data from 29,266 cases and 
56,450 controls. 
Exposures included directly measured circulating vitamin B12 in pre-diagnostic blood 
samples from the nested case-control study, and 8 single nucleotide polymorphisms 
associated with vitamin B12 concentrations in the MR study. 
Our main outcome of interest was increased risk for lung cancer, overall and by 
histological subtype, per increase in circulating vitamin B12 concentrations. 
We found circulating vitamin B12 to be positively associated with overall lung cancer 
risk in a dose response fashion (odds ratio for a doubling in B12 [ORlog2B12] = 1.15, 95% 
confidence interval (95%CI) = 1.06-1.25). The MR analysis based on 8 genetic variants also 
indicated that genetically determined higher vitamin B12 concentrations were positively 
associated with overall lung cancer risk (OR per 150 pmol/L standard deviation increase in 
B12 [ORSD]= 1.08, 95%CI= 1.00-1.16).  
Considering the consistency of these two independent and complementary analyses, 









The potential role of B vitamins in relation to cancer risk has been reported 
previously.1-3 Two large randomized controlled trials of B vitamin supplementation in 
Norway identified an increased risk for overall cancer among subjects who received both 
vitamin B12 and B9 (folate), a result that was primarily driven by lung cancer.4 More 
recently the Vitamins and Lifestyle (VITAL) cohort study5 reported increased lung cancer 
risks among men who used high amounts of vitamin B12 and B6 supplementation. These 
results4,5 argue against any chemo preventive effect of vitamin B12 in lung cancer, and 
instead are consistent with high concentrations of vitamin B12 increasing risk.  
To further elucidate the role of vitamin B12 in lung cancer etiology, we conducted two 
large and complementary analyses based on (i) directly measured circulating vitamin B12 
concentrations in pre-diagnostic samples from over 5,000 case-control pairs, and (ii) a 
Mendelian randomization (MR) analysis based on genetic data on close to 30,000 cases 
and 60,000 controls. 
Materials and Methods 
The first analysis was based on 5,364 lung cancer cases and 5,364 controls that 
were individually matched by age, sex, cohort, and smoking status. This sample was 
nested within 20 individual prospective cohort studies participating in the Lung Cancer 
Cohort Consortium (LC3), which was initially established to interrogate a potential inverse 
relation between circulating concentrations of B6 and B9 with lung cancer risk.6, 7 
The current study involved centralized biochemical analyses on pre-diagnostic 
serum/plasma samples and their individually matched controls using a microbiological 
assay to measure circulating concentrations of vitamin B12, 8 as well as a Liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) based assay9 to measure 




B12 (> 850 pmol/L, n=174), a total of 5,183 case-control pairs remained for the current 
study (Table 1). To evaluate the relation between directly measured vitamin B12 and lung 
cancer risk we used conditional logistic regression, additionally adjusted for educational 
attainment and tobacco exposure (smoking matched by design, as well as cotinine 
concentrations). Adjusting for body mass index and alcohol intake status did not alter our 
estimates, and covariates indicating those risk factors were not included in the final model. 
P-value for trend was calculated with a continuous variable as base 2 logarithm of the 
circulating concentrations of vitamin B12.  
The second investigation involved an MR analysis based on extensive genome-wide data 
for lung cancer risk from 29,266 lung cancer cases and 56,450 controls of European 
descent. This extensive genetic data is available from the Transdisciplinary Research in 
Cancer of the Lung (TRICL) and The International Lung Cancer Consortium (ILCCO) 
collaborations (Table 1).10 In the MR framework, genetic variants that are robustly 
associated with circulating vitamin B12 can be used as proxies and compared between 
cases and controls, rather than using direct measures of circulating B12 concentrations (as 
in LC3). The advantage of the MR methodology is that genetic variants are not affected by 
reverse causation of the disease and are less sensitive to confounding.11 Single nucleotide 
polymorphisms (SNP) for circulating vitamin B12 that were previously identified in European 
populations,12 including 8 independent SNPs (linkage disequilibrium R2<0.1), explained 
5.1% of circulating B12 variance12. The strength of this instrument was assessed by 
estimating an F-statistic (306.2), which, given the size of the instrument discovery sample 
(N=45,576) gave sufficient power (80%) to detect OR estimates for lung cancer overall 
(1.10), adenocarcinoma (1.15), squamous cell (1.17) and small cell carcinoma (1.20). The 
effects on lung cancer risk for predicted B12 vitamin concentrations were estimated using a 




deviation increase (SD) in vitamin B12 concentrations (150.1 pmol/L) based on the 
discovery study12. The instrumental SNPs could show heterogeneity of the estimated effect 
of vitamin B12 levels on lung cancer risk due to pleiotropic effects of these SNPs from other 
potential lung cancer risk factors. Thus, sensitivity analyses were performed to assess 
potential bias (non-balanced pleiotropic effects) on our initial risk estimates.14 Additionally, 
we evaluated the association between the genetic proxies of vitamin B12 concentrations 
and smoking behaviour using summary statistics for genetic association with smoking 
parameters from the Tobacco and Genetics (TAG) Consortium dataset comprising 74,035 
participants15 using a similar MR approach. Finally, by way of reference with the GWAS 
catalogue (https://www.ebi.ac.uk/gwas/) we sought to identify previously reported 
associations between the 8 SNPs included in this analysis and other known lung cancer 
risk factors beyond smoking.  
 
Results 
Directly measured circulating vitamin B12 was positively associated with overall lung cancer 
risk in the LC3 consortium (OR for a doubling in vitamin B12 [ORlog2B12] = 1.15, 95% 
confidence interval [95%CI] = 1.06-1.25, Figure 1). Positive associations were seen for 
adenocarcinoma (ORlog2B12 [95%CI] = 1.14 [1.00-1.30]) and small-cell carcinoma (ORlog2B12 
[95%CI] = 1.20 [0.91-1.59]), but no association was seen for squamous cell carcinoma 
(ORlog2B12 [95%CI] = 1.00 [0.81-1.23]). Subsequent analyses indicated a positive dose-
response relation between directly measured circulating vitamin B12 and lung cancer risk 
(eTable1 in the Supplement) that was consistently seen among all women, former and 
current smokers, participants with time from blood draw <72 months and >120 months 






The MR analysis for circulating vitamin B12 based on 8 genetic variants was consistent with 
the LC3 results, showing that a one SD genetically predicted higher vitamin B12 
concentration was associated with an increase in overall lung cancer risk (ORSD [95%CI] = 
1.08 [1.00-1.16]). Similar to the LC3 analysis, the MR analysis stratified by histology 
suggested stronger associations for adenocarcinoma (ORSD [95%CI]= 1.23 [1.11-1.37]) and 
small-cell carcinoma (ORSD [95%CI]=  1.17 [0.96-1.41]), but not for squamous cell 
carcinoma (ORSD [95%CI]= 0.97 [0.86-1.10]; P value for heterogeneity= 0.01, Figure 1). The 
MR-Egger test did not indicate bias in the risk estimates due to pleiotropy for lung overall (P 
value for MR-Egger intercept [PInt]= 0.17), nor for any histological subtype (PInt> 0.11). 
Furthermore, genetically predicted higher vitamin B12 concentrations were not associated 
with smoking parameters (ORSD being a smoker [95%CI]= 1.00 [0.91-1.11]; number of extra 
cigarettes smoked per day [95%CI]= -0.13 [-0.82:0.57]), indicating that our MR results on 
lung cancer risk were not explained by smoking as a confounder. Finally, the GWAS 
catalogue did not list any other lung cancer risk factor in association with the 8 SNPs used 
for the current MR analysis. More specifically, the rs1801222 and rs602662 SNPs were 
associated with homocysteine levels in the one-carbon metabolism pathway, and pediatric 
autoimmune diseases, respectively. 
 
Discussion 
In summary, we performed two complementary and independent analyses to evaluate if 
elevated concentrations of vitamin B12 increased lung cancer risk.5 Circulating 
concentrations of vitamin B12, based on pre-diagnostic blood samples from the LC3 
consortium on over 5,000 case-control pairs, were positively associated with lung cancer 




sexes, former and current smokers, time from blood draw, and geographic region (eFigure 
1). Confirming these results, the MR analysis based on genetic data indicated that higher 
concentrations of vitamin B12 increased the risk of lung cancer, especially for 
adenocarcinoma and small-cell carcinoma, with no association seen for squamous cell 
carcinoma. Generalisability of our results to populations not represented in the data used 
for the current analyses should be made with caution.  
 
Conclusions 
Considering the consistency of these two independent and complementary analyses, as 
well as previously published studies,4,5 these findings support the hypothesis that higher 
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Table 1. Baseline and sample characteristics of study participants  
    LC3 participants  TRICL-ILCCO participants 
    No.(%) of participants in group No.(%) of participants in group  
Discrete variables Cases                     
(n=5183) 
Matched  
controls                
(n=5183) 
Cases                                  
(n=29266) 
Controls            
(n=56450) 
Sex         
  Men 2827 (54.5%) 2827 (54.5%) 
 18208 
(62.2%) 
27178 (48.1%)  
  Women 2356 (45.5%) 2356 (45.5%) 11058 (37.8%) 24072 (51.9%) 
Smoking status       
  Never 1267 (24.4%) 1267 (24.4%) 2355 (8.0%) 7504 (13.3%) 
  Ever (Former and current) 3916 (75.5%) 3916 (75.5%) 23223 (79.3%) 16964 (30.1%) 
        Former 1458 (28.1%) 1458 (28.1%)     
        Current 2458 (47.4%) 2458 (47.4%)     
Education       
  Less than high school 1746 (33.7%) 1643 (31.7%)   
  Completed high school 735 (14.2%) 754 (14.5%)   
  Vocational school 862 (16.6%) 886 (17.1%)   
  Some college 651 (12.6%) 698 (13.4%)   
  College graduate 499 (9.5%) 480 (9.2%)   
  Graduate studies 625 (12.2%) 677 (13.1%)   
  Unknown 65 (1.2%) 45 (1.0%)   
Continuous variables, median (5th-95th percentile)   
Age at recruitment (years) 60 (44-72) 60 (44-72) 88% higher than 55 
Vitamin B12 (pmol/L) 432 (239-747) 425 (231-733)   
Clinical characteristics, case participants only   
Age at diagnosis, median (range), (years) 69.7 (53.4 81.7)     
Time from blood draw to diagnosis (years) 6.4 (1.0-16.0)     
Histology, No. (%)       
  Large cell carcinoma 166 (3.4%)     
  Small cell carcinoma 481 (10.1%)   2664 (9.1%)  
  Squamous cell carcinoma 813 (17.0%)   7426 (25.4%)  
  Adenocarcinoma 1972 (41.2%)   11273 (38.5%)  






Figure 1 - Forest plot showing the relationship between circulating vitamin B12 and 
lung cancer risk from the LC3 and a Mendelian randomization analysis. 
 
Footnote: *LC3 odds ratios (OR) indicate relative risks of a doubling in circulating concentrations (base 2 
logarithm transformed) adjusted for cotinine and education when relevant (95%CI: 95% confidence intervals). † 
Mendelian randomization ORs indicate the odds for a one standard deviation (SD) increase in circulating 
concentrations (approximately 150 pmol/L). ‡ P heterogeneity indicates results of chi-square test assessing the 
null hypothesis of ORs being the identical.  
 
 
